Cliniphar (TSE:432A) ROCE %: 8.20% (As of Mar. 2026)


TSE:432A Cliniphar Ltd TSE:432A
20 GF Score
Price 円1,450.00
! 3 Warning Signs
View Full Analysis

What is Cliniphar ROCE %?

Cliniphar TSE:432A 20 ROCE % is 8.20% as of Mar. 2026. GuruFocus rates TSE:432A with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cliniphar's annualized ROCE % for the quarter that ended in Mar. 2026 was 8.20%.

Cliniphar  (TSE:432A) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cliniphar ROCE % Related Terms

Cliniphar ROCE % Historical Data

* Premium members only.

The historical data trend for Cliniphar's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cliniphar ROCE % Chart

Cliniphar Annual Data
Trend Mar24 Mar25 Mar26
ROCE %
-27.01 10.10 8.20

Cliniphar Semi-Annual Data
Mar24 Mar25 Mar26
ROCE % -27.01 10.10 8.20
TSE:432A
20GF Score
Cliniphar Ltd TSE:432A
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cliniphar ROCE % Calculation

Cliniphar's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=154.379/( ( (2662.045 - 595.147) + (2600.67 - 900.269) )/ 2 )
=154.379/( (2066.898+1700.401)/ 2 )
=154.379/1883.6495
=8.20 %

Cliniphar's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Mar. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Mar. 2025 )(Q: Mar. 2026 )
=154.379/( ( (2662.045 - 595.147) + (2600.67 - 900.269) )/ 2 )
=154.379/( ( 2066.898 + 1700.401 )/ 2 )
=154.379/1883.6495
=8.20 %

(1) Note: The EBIT data used here is one times the annual (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 8.20% mean?
Cliniphar (TSE:432A) has a ROCE % of 8.20% as of Mar. 2026.
Is Cliniphar's ROCE % too high?
Cliniphar's current ROCE % is 8.20%. The Healthcare Providers & Services industry median ROCE % is 6.41. Cliniphar's value of 8.20% is 27.9% above this industry median. Overall, Cliniphar has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Cliniphar's ROCE % compare to competitors?
Cliniphar's ROCE % of 8.20% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. Cliniphar's value of 8.20% is 27.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 646 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cliniphar's current ROCE % of 8.20% is 27.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cliniphar's current ROCE % is 8.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cliniphar stock overvalued right now?
Cliniphar (TSE:432A) has a current ROCE % of 8.20%. The current ROCE % is 8.20% and 27.9% above the Healthcare Providers & Services industry median of 6.41. Cliniphar's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Cliniphar (TSE:432A), the current ROCE % is 8.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cliniphar Business Description

Address 1-7-31, Otemae, 5th Floor, OMM Building, Otemae, Chuo-ku, Osaka-shi, Osaka, JPN, 540-0008
Cliniphar Ltd is engaged in Pharmaceutical Wholesale and Distribution Business for Domestic and International Markets.
20GF Score

Get the complete analysis for TSE:432A

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,450.00
Price